<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029054</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2009.056</org_study_id>
    <secondary_id>HUM30396</secondary_id>
    <nct_id>NCT01029054</nct_id>
  </id_info>
  <brief_title>Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma</brief_title>
  <official_title>Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and to determine the maximum tolerated dose of&#xD;
      carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple&#xD;
      Myeloma patients who have not received treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the Phase I portion of this clinical trial, the dose of Revlimid® and carfilzomib will&#xD;
      be increased until the best and safest amount (or dose) is identified in combination with&#xD;
      standard doses of Revlimid® and dexamethasone. &quot;Investigational&quot; means that the drug&#xD;
      combination is still being studied and that research doctors are trying to find out more&#xD;
      about it such as the safest dose to use, the side effects it may cause and how effective the&#xD;
      Revlimid® and carfilzomib and dexamethasone investigational combination is for treating newly&#xD;
      diagnosed multiple myeloma. In this clinical trial we are looking for the highest dose of the&#xD;
      combination that can be given safely and see how well it works as a combination in newly&#xD;
      diagnosed patients.&#xD;
&#xD;
      The drug, carfilzomib, has not yet been approved by the FDA (U.S. Food and Drug&#xD;
      Administration). Revlimid® and Dexamethasone have been approved by the FDA. The drugs have&#xD;
      not been approved in this combination for use for your type of cancer or any other type of&#xD;
      cancer. Carfilzomib is being researched to treat multiple myeloma. Dexamethasone is commonly&#xD;
      used, either alone, or in combination with other drugs, to treat multiple myeloma. Revlimid®&#xD;
      is currently approved by the US FDA in combination with dexamethasone for the treatment of&#xD;
      patients with multiple myeloma who have received at least 1 prior therapy.&#xD;
&#xD;
      After the Phase I clinical trial defines the safest doses of Revlimid® and carfilzomib and&#xD;
      dexamethasone that can be taken together, the research study will move on to its second&#xD;
      portion, a Phase II clinical trial. The Phase II portion of the clinical trial will test the&#xD;
      clinical effectiveness of the best dose combination of the three drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Maximum Tolerated Dose (MTD) of Carfilzomib</measure>
    <time_frame>6 Months</time_frame>
    <description>Determine the MTD of Carfilzomib when combined with Lenalidomide and Dexamethasone. The estimated time to determine the MTD is 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Patients That Achieve a Response to Treatment</measure>
    <time_frame>4 Months After Treatment Start</time_frame>
    <description>The percentage of patients that achieve at least a sCR (Stringent Complete Response), at least a VGPR (Very Good Partial Response) and at least a PR (Partial Response) will be determined.&#xD;
sCR is defined as:&#xD;
Negative immunofixation on the serum and urine and&#xD;
Disappearance of any soft tissue plasmacytomas and&#xD;
&lt; 5% plasma cells in bone marrow and&#xD;
Normal SFLC ratio and&#xD;
Absence of clonal cells in bone marrow&#xD;
VGPR is defined as:&#xD;
Serum and urine M-protein detectable by immunofixation but not on electrophoresis or&#xD;
≥ 90% reduction in serum M-component with urine M-component &lt; 100 mg per 24 hours&#xD;
PR is defined as:&#xD;
≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to &lt; 200 mg per 24 hours&#xD;
If present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients Alive Without Progression</measure>
    <time_frame>12 Months and 24 Months Post Treatment</time_frame>
    <description>The Progression Free Survival (PFS) rate will be determined at 12 and 24 months post treatment.&#xD;
Progressive Disease (PD) is defined as an increase of greater than or equal to 25% from lowest response level in serum M-component and/ or urine M-component and/ or the difference between involved or uninvolved SFLC levels and/ or bone marrow % plasma cells. PD may also be the development of new bone lesions or soft tissue plasmacytomas or the increase in size of existing lesions. PD may also be the development of hypercalcemia.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>carfilzomib, lenalidomide w/dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: carfilzomib will be taken with a combination of lenalidomide plus dexamethasone in a series of escalating dosages to determine the maximum tolerated dose level&#xD;
Phase II: carfilzomib will be given at the MTD established in the Phase I portion of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carfilzomib, lenalidomide plus dexamethasone</intervention_name>
    <description>Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.</description>
    <arm_group_label>carfilzomib, lenalidomide w/dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carfilzomib, lenalidomide plus dexamethasone</intervention_name>
    <description>Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg.</description>
    <arm_group_label>carfilzomib, lenalidomide w/dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Newly diagnosed, histologically confirmed, previously untreated Stage I, II, or III&#xD;
             multiple myeloma requiring systemic chemotherapy&#xD;
&#xD;
          2. Diagnosis of symptomatic multiple myeloma per IMWG uniform criteria within the past 90&#xD;
             days&#xD;
&#xD;
          3. Measurable disease, per IMWG (International Myeloma Working Group) criteria (&gt;= one of&#xD;
             the following) within the past 4 weeks:&#xD;
&#xD;
               -  Monoclonal protein &gt;= 0.5 g/dL by serum protein electrophoresis&#xD;
&#xD;
               -  Monoclonal light chain &gt;= 200 mg by 24-hour urine protein electrophoresis&#xD;
&#xD;
               -  If serum protein electrophoresis is felt to be unreliable for routine M-protein&#xD;
                  measurement, then quantitative immunoglobulin levels are acceptable&#xD;
&#xD;
          4. Life expectancy &gt; 3 months&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          6. Adequate hepatic function, with bilirubin &lt; 1.5 x the ULN, and AST (Aspartate&#xD;
             Aminotransferase) and ALT (Alanine Transaminase) &lt; 2.5 x ULN&#xD;
&#xD;
          7. Absolute neutrophil count (ANC) &gt;=1.0 x 109/L, hemoglobin &gt;= 8 g/dL, platelet count &gt;=&#xD;
             75 x 109/L&#xD;
&#xD;
          8. Calculated creatinine clearance (by Cockroft-Gault) &gt;= 60 ml/min&#xD;
&#xD;
          9. Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines.&#xD;
&#xD;
         10. Subjects must agree to adhere to all study requirements, including birth control&#xD;
             measures and pregnancy testing, visit schedule, outpatient treatment, required&#xD;
             concomitant medications, and laboratory monitoring.&#xD;
&#xD;
         11. Must be able to take either 81 mg or 325 mg aspirin daily as prophylactic&#xD;
             anticoagulation.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Non-secretory or hyposecretory multiple myeloma, defined as &lt;0.5 g/dL M-protein in&#xD;
             serum, &lt;200 mg/24 hr urine M-protein, or disease only measured by serum free light&#xD;
             chain&#xD;
&#xD;
          2. POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin&#xD;
             Changes) syndrome&#xD;
&#xD;
          3. Plasma cell leukemia&#xD;
&#xD;
          4. Waldenström's macroglobulinemia or IgM myeloma&#xD;
&#xD;
          5. Radiotherapy to multiple sites or immunotherapy within 2 weeks before start of&#xD;
             protocol treatment (localized radiotherapy to a single site at least 1 week before&#xD;
             start is permissible)&#xD;
&#xD;
          6. Patient must not have been previously treated with any prior systemic therapy for the&#xD;
             treatment of multiple myeloma&#xD;
&#xD;
               -  Prior treatment of hypercalcemia or spinal cord compression or aggressively&#xD;
                  progressing myeloma with corticosteroids does not disqualify the patient (the&#xD;
                  dose should not exceed the equivalent of 160 mg of dexamethasone in a 2 week&#xD;
                  period)&#xD;
&#xD;
               -  Bisphosphonates are permitted&#xD;
&#xD;
          7. Participation in an investigational therapeutic study within 3 weeks or within 5 drug&#xD;
             halflives (t1/2) prior to first dose, whichever time is greater&#xD;
&#xD;
          8. Pregnant or lactating females&#xD;
&#xD;
          9. History of allergy to mannitol&#xD;
&#xD;
         10. Major surgery within 3 weeks prior to first dose&#xD;
&#xD;
         11. Myocardial infarction within 3 months prior to enrollment, NYHA (New York Heart&#xD;
             Association) Class III or IV heart failure, uncontrolled angina, severe uncontrolled&#xD;
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active&#xD;
             conduction system abnormalities&#xD;
&#xD;
         12. Uncontrolled hypertension or diabetes&#xD;
&#xD;
         13. Acute active infection requiring systemic antibiotics, antivirals, or antifungals&#xD;
             within two weeks prior to first dose&#xD;
&#xD;
         14. Known or suspected HIV infection, known HIV seropositivity&#xD;
&#xD;
         15. Active hepatitis infection&#xD;
&#xD;
         16. Non-hematologic malignancy within the past 3 years except a) adequately treated basal&#xD;
             cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or&#xD;
             prostate cancer &lt; Gleason Grade 6 with stable prostate specific antigen levels or&#xD;
             cancer considered cured by surgical resection alone&#xD;
&#xD;
         17. Any clinically significant medical disease or condition that, in the Investigator's&#xD;
             opinion, may interfere with protocol adherence or a subject's ability to give informed&#xD;
             consent&#xD;
&#xD;
         18. Significant neuropathy (Grade &gt;2) at the time of the first dose and/or within 14 days&#xD;
             before enrollment&#xD;
&#xD;
         19. Contraindication to any of the required concomitant drugs&#xD;
&#xD;
         20. Subjects in whom the required program of PO and IV fluid hydration is contraindicated&#xD;
&#xD;
         21. Subjects with known or suspected amyloidosis of any organ&#xD;
&#xD;
         22. Subjects with pleural effusions requiring thoracentesis or ascites requiring&#xD;
             paracentesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Kaminski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <results_first_submitted>November 13, 2014</results_first_submitted>
  <results_first_submitted_qc>November 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2014</results_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Escalation Cohort 1</title>
          <description>Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance) at dose level 20 mg/m^2.&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.</description>
        </group>
        <group group_id="P2">
          <title>Dose Escalation Cohort 2</title>
          <description>Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance) at dose level 27 mg/m^2.&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.</description>
        </group>
        <group group_id="P3">
          <title>Dose Escalation Cohort 3</title>
          <description>Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance) at dose level 36 mg/m^2.&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="18">35 participants were enrolled in Ph I. 18 additional participants were enrolled in Ph II at the MTD.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carfilzomib, Lenalidomide w/Dexamethasone</title>
          <description>Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="35" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Maximum Tolerated Dose (MTD) of Carfilzomib</title>
        <description>Determine the MTD of Carfilzomib when combined with Lenalidomide and Dexamethasone. The estimated time to determine the MTD is 6 months.</description>
        <time_frame>6 Months</time_frame>
        <population>Of the 53 patients enrolled, 35 were entered into the Phase I portion of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib, Lenalidomide w/Dexamethasone</title>
            <description>Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Tolerated Dose (MTD) of Carfilzomib</title>
          <description>Determine the MTD of Carfilzomib when combined with Lenalidomide and Dexamethasone. The estimated time to determine the MTD is 6 months.</description>
          <population>Of the 53 patients enrolled, 35 were entered into the Phase I portion of the study.</population>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients Alive Without Progression</title>
        <description>The Progression Free Survival (PFS) rate will be determined at 12 and 24 months post treatment.&#xD;
Progressive Disease (PD) is defined as an increase of greater than or equal to 25% from lowest response level in serum M-component and/ or urine M-component and/ or the difference between involved or uninvolved SFLC levels and/ or bone marrow % plasma cells. PD may also be the development of new bone lesions or soft tissue plasmacytomas or the increase in size of existing lesions. PD may also be the development of hypercalcemia.</description>
        <time_frame>12 Months and 24 Months Post Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib, Lenalidomide w/Dexamethasone</title>
            <description>Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients Alive Without Progression</title>
          <description>The Progression Free Survival (PFS) rate will be determined at 12 and 24 months post treatment.&#xD;
Progressive Disease (PD) is defined as an increase of greater than or equal to 25% from lowest response level in serum M-component and/ or urine M-component and/ or the difference between involved or uninvolved SFLC levels and/ or bone marrow % plasma cells. PD may also be the development of new bone lesions or soft tissue plasmacytomas or the increase in size of existing lesions. PD may also be the development of hypercalcemia.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Patients Without Progression at 12 m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Patients Without Progression at 24 m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients That Achieve a Response to Treatment</title>
        <description>The percentage of patients that achieve at least a sCR (Stringent Complete Response), at least a VGPR (Very Good Partial Response) and at least a PR (Partial Response) will be determined.&#xD;
sCR is defined as:&#xD;
Negative immunofixation on the serum and urine and&#xD;
Disappearance of any soft tissue plasmacytomas and&#xD;
&lt; 5% plasma cells in bone marrow and&#xD;
Normal SFLC ratio and&#xD;
Absence of clonal cells in bone marrow&#xD;
VGPR is defined as:&#xD;
Serum and urine M-protein detectable by immunofixation but not on electrophoresis or&#xD;
≥ 90% reduction in serum M-component with urine M-component &lt; 100 mg per 24 hours&#xD;
PR is defined as:&#xD;
≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to &lt; 200 mg per 24 hours&#xD;
If present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required</description>
        <time_frame>4 Months After Treatment Start</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib, Lenalidomide w/Dexamethasone</title>
            <description>Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients That Achieve a Response to Treatment</title>
          <description>The percentage of patients that achieve at least a sCR (Stringent Complete Response), at least a VGPR (Very Good Partial Response) and at least a PR (Partial Response) will be determined.&#xD;
sCR is defined as:&#xD;
Negative immunofixation on the serum and urine and&#xD;
Disappearance of any soft tissue plasmacytomas and&#xD;
&lt; 5% plasma cells in bone marrow and&#xD;
Normal SFLC ratio and&#xD;
Absence of clonal cells in bone marrow&#xD;
VGPR is defined as:&#xD;
Serum and urine M-protein detectable by immunofixation but not on electrophoresis or&#xD;
≥ 90% reduction in serum M-component with urine M-component &lt; 100 mg per 24 hours&#xD;
PR is defined as:&#xD;
≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to &lt; 200 mg per 24 hours&#xD;
If present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of patients that achieve at least a sCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of patients that achieve at least a VGPR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of patients that achieve at least a PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AEs) that occurred after the subject signed consent were documented.</time_frame>
      <desc>A Serious Adverse Event (SAE) is defined as: death, a life-threatening experience, hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of an exposed subject, important medical events based upon appropriate medical judgment, pregnancy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Carfilzomib, Lenalidomide w/Dexamethasone</title>
          <description>Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).&#xD;
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.&#xD;
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Methemoglobinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rapid Ventricular Response</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Mental Status Change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Grand Mal Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pulmonary Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Function Test</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Cramping</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Alterations</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Kaminski, M.D.</name_or_title>
      <organization>University of Michigan Hospital</organization>
      <phone>734-936-5310</phone>
      <email>mkaminsk@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

